Amitriptyline

Amitriptyline is one of the classic tricyclic antidepressants, named for the three-ring core of its structure. It reached the market in 1961 as an early treatment for major depressive disorder and became a benchmark against which newer antidepressants were compared ^[1][2]. Over time, safer drugs such as the selective serotonin reuptake inhibitors displaced it as a first-choice antidepressant, but amitriptyline remains in wide use, particularly for pain, and appears on the World Health Organization's list of essential medicines ^[1].

The drug's main antidepressant action is to block the reuptake of serotonin and norepinephrine, raising the levels of these messengers in the brain; its active breakdown product, nortriptyline, is itself an antidepressant with a stronger effect on norepinephrine ^[1]. Amitriptyline also blocks histamine, muscarinic acetylcholine, and alpha-1 adrenergic receptors, interactions that produce sedation, dry mouth, constipation, and a drop in blood pressure on standing, and it affects cardiac ion channels, which makes it dangerous in overdose ^[1].

Beyond depression, amitriptyline is a mainstay of chronic pain management. It has long been a first-line option for neuropathic pain, used at doses lower than those needed for depression, though systematic reviews note that rigorous, unbiased trials are limited and that only a minority of people achieve satisfactory relief ^[3]. Similar conclusions apply to fibromyalgia, where some benefit is seen despite modest trial quality ^[4]. The drug is also used to prevent migraine and tension-type headaches and, off-label, for insomnia, bedwetting in children, and irritable bowel syndrome.

For its original indication, the evidence is firmer. A large systematic review of placebo-controlled trials confirmed that amitriptyline is an effective antidepressant, while also documenting that it causes more side effects and more withdrawals due to those effects than placebo ^[2]. This balance of strong efficacy against a heavy side-effect burden is the reason it is now usually reserved for use after better-tolerated drugs have failed.

Amitriptyline is a prescription-only medicine available cheaply as a generic, in oral tablet form and sometimes combined with other agents. Because of its narrow margin of safety in overdose and its anticholinergic effects, it is prescribed with particular caution in older adults and in people at risk of self-harm ^[1].

Amitriptyline is a prescription tricyclic and its wide receptor activity means more side effects than newer options. Drowsiness, dry mouth, constipation, blurred vision, urinary hesitancy, weight gain, and dizziness on standing are common, largely from its anticholinergic and antihistamine actions. It can affect heart rhythm and prolong the QT interval, so it is used cautiously in heart disease and the elderly, and it is dangerous in overdose. It must not be combined with MAOIs, and it should be tapered rather than stopped abruptly. Starting low and dosing at night helps with both tolerance and sleep.

Terbinafine inhibits CYP2D6, the primary enzyme metabolizing amitriptyline, causing prolonged and elevated plasma concentrations. Nortriptyline (amitriptyline's metabolite) levels increased by up to 2.5-fold during concurrent terbinafine therapy and remained elevated for months after terbinafine cessation, reaching toxic levels ^[6]. This is a pharmacokinetic interaction with time-dependent effects. CYP2C19 inhibitors like anwuligan similarly increase amitriptyline AUC by 1.4-fold ^[7]. The combination of amitriptyline with monoamine oxidase inhibitors poses a serious pharmacodynamic risk of serotonin syndrome, though detailed clinical interaction studies are limited. Drug combinations with sympathomimetics, anticholinergics, and alcohol are widely cautioned in FDA labeling but lack robust published quantitative data.

Checking a whole stack? Run it through interactions + stacks.

Amitriptyline was synthesized by Merck and introduced in the United States in 1961, making it one of the earliest tricyclic antidepressants to reach clinical practice. It emerged during the first wave of antidepressant discovery in the late 1950s and 1960s, alongside imipramine, when the mood-lifting properties of dibenzocycloheptene and related three-ringed structures were being explored. Marketed under the brand name Elavil, it was first developed for major depression, but clinicians soon recognized that its sedating quality and pain-relieving effects made it useful well beyond mood disorders. Over the following decades its role shifted; today it is prescribed at least as often for chronic pain, migraine prophylaxis, and sleep as for depression itself. It remains listed on the World Health Organization Model List of Essential Medicines.

Amitriptyline is regarded as a durable and versatile medicine that has kept a place in practice for more than sixty years despite the arrival of newer, cleaner antidepressants. Physicians value it particularly in neuropathic pain, fibromyalgia, and headache prevention, where low bedtime doses can ease symptoms and improve sleep at the same time. Its long track record means its behavior and its side effects are exceptionally well characterized, which many clinicians find reassuring. It is honestly not a gentle drug; its anticholinergic burden, sedation, and danger in overdose call for careful dosing, yet used thoughtfully it remains one of the more reliable tools for difficult pain and low mood.